Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$1.68 -0.07 (-4.00%)
As of 08/14/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$1.75
$1.78
50-Day Range
$1.76
$2.32
52-Week Range
$1.20
$4.05
Volume
1,305 shs
Average Volume
18,115 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    CytoMed Therapeutics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.82% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 27.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.82% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 27.29%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CytoMed Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for CytoMed Therapeutics this week, compared to 0 articles on an average week.
Receive GDTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GDTC Stock News Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Headlines

GDTC Stock Analysis - Frequently Asked Questions

CytoMed Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, GDTC stock has decreased by 47.9% and is now trading at $1.77.

CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering (IPO) on Friday, April 14th 2023. The company issued 2,412,369 shares at $4.00 per share.

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

Today
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GDTC
CIK
1873093
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+182.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
9.89
Quick Ratio
9.89

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
2.90

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.38

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:GDTC) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners